Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM
Status:
Completed
Trial end date:
2018-12-05
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to document the efficacy of NGR-hTNF administered as
maintenance treatment at 0.8 µg/m2 weekly in advanced malignant pleural mesothelioma